利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

70 条记录 (耗时 0.033 秒)

    Anti-Mesothelin Antibodies
    61.
    发明申请
    Anti-Mesothelin Antibodies 有权
    抗间皮素抗体

    公开(公告)号：US20120237509A1

    公开(公告)日：2012-09-20

    申请号：US13476656

    申请日：2012-05-21

    申请人： Wolfgang Ebel ,  Luigi Grasso ,  Nicholas C. Nicolaides ,  Philip M. Sass ,  Eric Routhier

    发明人： Wolfgang Ebel ,  Luigi Grasso ,  Nicholas C. Nicolaides ,  Philip M. Sass ,  Eric Routhier

    IPC分类号： A61K39/395 ,  C12N5/10 ,  C12N15/63 ,  C12N15/13 ,  A61P35/00

    CPC分类号： C07K16/28 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3069 ,  C07K2317/56 ,  C07K2317/732 ,  C07K2317/77

    摘要： This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and become internalized by mesothelin-positive cells and also induce an immune effector activity such as antibody dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to mesothelin expressing cells as well as eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to cells expressing the monoclonal antibodies, polyclonal antibodies, antibody derivatives, such as human, humanized, and chimeric monoclonal antibodies, antibody fragments, mammalian cells expressing the monoclonal antibodies, derivatives and fragments, and methods of treating cancer using the antibodies, derivatives and fragments.

    摘要翻译： 本发明涉及单克隆和多克隆抗体的使用，其特异性结合并被间皮素阳性细胞内化，并且还诱导免疫效应子活性如抗体依赖性细胞毒性。 该抗体可用于特异性递送表达间皮素的药物学药剂，以及引发免疫效应物特异性对肿瘤细胞和前体的活性。 本发明还涉及表达单克隆抗体，多克隆抗体，抗体衍生物如人，人源化和嵌合单克隆抗体的细胞，抗体片段，表达单克隆抗体的哺乳动物细胞，衍生物和片段，以及使用 抗体，衍生物和片段。

    Antibodies and methods for generating genetically altered antibodies with high affinity
    64.
    发明授权
    Antibodies and methods for generating genetically altered antibodies with high affinity 有权
    用于产生具有高亲和力的遗传改变的抗体的抗体和方法

    公开(公告)号：US07671179B2

    公开(公告)日：2010-03-02

    申请号：US11746868

    申请日：2007-05-10

    申请人： Nicholas C. Nicolaides ,  Luigi Grasso ,  Philip M. Sass

    发明人： Nicholas C. Nicolaides ,  Luigi Grasso ,  Philip M. Sass

    IPC分类号： C07K16/18

    CPC分类号： C12N15/01 ,  C07K16/00 ,  C07K16/4291 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/92 ,  C12N15/1024

    摘要： Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals, new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production. The invention also provides methods for increasing the affinity of monoclonal antibodies and monoclonal antibodies with increased affinity.

    摘要翻译： 人类错配修复基因的主要阴性等位基因可用于产生超可变细胞和生物体。 通过将这些基因引入细胞和转基因动物，可以比通过依赖于突变的自然速率更有效地制备具有新颖和有用性质的新细胞系和动物品种。 这些方法可用于在针对感兴趣的抗原的免疫球蛋白基因内产生遗传多样性，以产生具有增强的生化活性的改变的抗体。 此外，这些方法可用于产生具有增加的抗体产生水平的产生抗体的细胞。 本发明还提供了增加亲和力的单克隆抗体和单克隆抗体的亲和力的方法。

    Genetically Altered Anti-body Producing Cell Lines With Improved Antibody Characteristics
    65.
    发明申请
    Genetically Altered Anti-body Producing Cell Lines With Improved Antibody Characteristics 审中-公开
    基因改造的抗体生产细胞系具有改善的抗体特征

    公开(公告)号：US20100021996A1

    公开(公告)日：2010-01-28

    申请号：US12566167

    申请日：2009-09-24

    申请人： Luigi Grasso ,  Nicholas C. Nicolaides ,  Philip M. Sass

    发明人： Luigi Grasso ,  Nicholas C. Nicolaides ,  Philip M. Sass

    IPC分类号： C12N5/16

    CPC分类号： C12N15/1024 ,  C07H21/04 ,  C07K16/00 ,  C07K16/4291 ,  C12N5/12 ,  C12N2501/052 ,  C12N2501/15 ,  C12N2501/23 ,  C12N2501/52 ,  C12N2510/02

    摘要： Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. Cells may be selected for expression of activation-induced cytidine deaminase (AID), stimulated to produce AID, or manipulated to express AID for further enhancement of hypermutability. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production.

    摘要翻译： 人类错配修复基因的主要阴性等位基因可用于产生超可变细胞和生物体。 可以选择细胞用于表达活化诱导的胞苷脱氨酶（AID），刺激产生AID，或操纵以表达AID以进一步增强超敏性。 这些方法可用于在针对感兴趣的抗原的免疫球蛋白基因内产生遗传多样性，以产生具有增强的生化活性的改变的抗体。 此外，这些方法可用于产生具有增加的抗体产生水平的产生抗体的细胞。

    Antibodies with immune effector activity and that internalize in endosialin-positive cells
    67.
    发明授权
    Antibodies with immune effector activity and that internalize in endosialin-positive cells 有权
    具有免疫效应子活性的抗体，并且在内皮细胞内阳性细胞内部化

    公开(公告)号：US07615372B2

    公开(公告)日：2009-11-10

    申请号：US11410472

    申请日：2006-04-24

    申请人： Nicholas C. Nicolaides ,  Luigi Grasso ,  Philip M. Sass

    发明人： Nicholas C. Nicolaides ,  Luigi Grasso ,  Philip M. Sass

    IPC分类号： C12N15/85

    CPC分类号： A61K39/39583 ,  A61K47/6825 ,  A61K47/6897 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/28 ,  C07K16/2851 ,  C07K2317/732 ,  C07K2317/77

    摘要： This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to endosialin-expressing cells as well as in eliciting an immune-effector activity particularly on tumor and neovascular cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer and neovascular cells; and methods of treating cancer and neovascular disease using the antibodies, derivatives and fragments.

    摘要翻译： 本发明涉及单克隆抗体和多克隆抗体的用途，其特异性结合并具有替代性的能力，其通过表达内质网蛋白的细胞内化并诱导免疫效应物活性如抗体依赖性细胞毒性。 抗体可用于特异性递送药物剂至表达唾液酸的细胞，以及引发免疫效应物特异性对肿瘤和新生血管细胞和前体的活性。 本发明还涉及编码本发明抗体的核苷酸，表达抗体的细胞; 检测癌症和新血管细胞的方法; 以及使用抗体，衍生物和片段治疗癌症和新生血管疾病的方法。

    METHODS FOR ISOLATING NOVEL ANTIMICROBIAL AGENTS FROM HYPERMUTABLE MAMMALIAN CELLS
    68.
    发明申请
    METHODS FOR ISOLATING NOVEL ANTIMICROBIAL AGENTS FROM HYPERMUTABLE MAMMALIAN CELLS 有权
    从高可控性母体细胞中分离新型抗微生物剂的方法

    公开(公告)号：US20080182242A1

    公开(公告)日：2008-07-31

    申请号：US11736888

    申请日：2007-04-18

    申请人： Nicholas C. Nicolaides ,  Luigi Grasso ,  Philip M. Sass

    发明人： Nicholas C. Nicolaides ,  Luigi Grasso ,  Philip M. Sass

    IPC分类号： C12Q1/68

    CPC分类号： C07K14/47 ,  C12N15/01 ,  C12N15/102

    摘要： Dominant-negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into mammalian cells new cell lines with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation or introduction of mutations by chemical mutagens. These methods are useful for generating novel and highly active antimicrobial molecules as well as superior antimicrobial agents from pre-existing chemicals. These methods are also useful for generating cell lines expressing novel antimicrobials that are useful for pharmaceutical manufacturing.

    摘要翻译： 人类错配修复基因的显性阴性等位基因可用于产生超可变细胞和生物体。 通过将这些基因引入哺乳动物细胞，可以比通过依赖于天然的突变率或通过化学诱变剂引入突变更有效地制备具有新颖和有用性质的新细胞系。 这些方法可用于产生新的和高活性的抗微生物分子以及来自预先存在的化学物质的优良的抗微生物剂。 这些方法也可用于产生表达可用于药物制造的新型抗微生物剂的细胞系。

    ANTI-FOLATE RECEPTOR ALPHA ANTIBODY GLYCOFORMS
    69.
    发明申请
    ANTI-FOLATE RECEPTOR ALPHA ANTIBODY GLYCOFORMS 审中-公开
    抗体受体ALPHA抗体GLYCOFORFORM

    公开(公告)号：US20120164137A1

    公开(公告)日：2012-06-28

    申请号：US13277161

    申请日：2011-10-19

    申请人： Philip M. Sass ,  Nicholas Nicolaides ,  Luigi Grasso ,  Eric Routhier ,  Wei Gu ,  Jason Young ,  Jun Yao

    发明人： Philip M. Sass ,  Nicholas Nicolaides ,  Luigi Grasso ,  Eric Routhier ,  Wei Gu ,  Jason Young ,  Jun Yao

    IPC分类号： A61K39/395 ,  C12N5/10 ,  A61P35/02 ,  A61P35/00 ,  G01N33/566 ,  G01N33/574 ,  C07K16/28 ,  C12P21/08

    CPC分类号： C07K16/28 ,  C07K16/00 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/77

    摘要： The invention provides anti-FRA antibodies with novel N-linked neutral glycan profiles in that the relative amounts of one or more neutral glycans are increased or decreased compared to anti-FRA antibodies produced under reference cell culture conditions. The invention further provides anti-FRA antibodies with altered binding to FRA, altered antibody-dependent cellular cytotoxicity (ADCC) and/or altered rate and/or efficiency of internalization in a cell expressing FRA. In related aspects, the invention provides cell cultures comprising an anti-FRA antibody of the invention, a cell isolated from such a culture, kits and compositions comprising an anti-FRA antibody of the invention, methods of producing an anti-FRA antibody of the invention and diagnostic and therapeutic uses of an anti-FRA antibody of the invention.

    摘要翻译： 本发明提供具有新型N-连接的中性聚糖谱的抗FRA抗体，因为与参考细胞培养条件下产生的抗FRA抗体相比，一种或多种中性聚糖的相对量增加或减少。 本发明还提供具有改变的FRA结合，改变的抗体依赖性细胞毒性（ADCC）和/或表达FRA的细胞中内化的速率和/或效率的改变的抗FRA抗体。 在相关方面，本发明提供包含本发明的抗FRA抗体的细胞培养物，从这种培养物分离的细胞，包含本发明的抗FRA抗体的试剂盒和组合物，制备本发明的抗FRA抗体的方法 本发明的抗FRA抗体的发明和诊断和治疗用途。